Nasal spray shows promise against suicidal thoughts – but who benefits most?

NCT ID NCT07199179

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a nasal spray called esketamine can quickly reduce suicidal thoughts in people with severe depression. Researchers want to find out if symptoms like loss of pleasure (anhedonia) or emotional pain can predict who will benefit most. The study re-analyzes data from two earlier trials involving 456 patients. It does not test a new treatment but aims to better understand how esketamine works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chu Montpellier

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.